(Q38131710)

29 August 2017

Pathophysiology and treatment of systemic amyloidosis (English)

1 reference

29 August 2017

1 reference

Julian D Gillmore

1

1 reference

PubMed ID

23979488

29 August 2017

Philip N Hawkins

series ordinal

2

1 reference

PubMed ID

23979488

29 August 2017

language of work or name

English

0 references

publication date

27 August 2013

1 reference

Nature Reviews Nephrology

29 August 2017

1 reference

29 August 2017

9

1 reference

29 August 2017

574-586

1 reference

29 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2013.171

29 August 2017

0 references

cites work

Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Molecular mechanisms of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Susceptibility to AA amyloidosis in rheumatic diseases: a critical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Protein misfolding, functional amyloid, and human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Biology of amyloid: structure, function, and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloid P component. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Antibodies to human serum amyloid P component eliminate visceral amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Kinetic analysis of amyloid formation in the presence of heparan sulfate: faster unfolding and change of pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Heparan sulfate promotes the aggregation of HDL-associated serum amyloid A: evidence for a proamyloidogenic histidine molecular switch

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Heparan sulfate/heparin promotes transthyretin fibrillization through selective binding to a basic motif in the protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloidogenesis: historical and modern observations point to heparan sulfate proteoglycans as a major culprit

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Search for amyloid-binding proteins by affinity chromatography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

A primed state exists in vivo following histological regression of amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Only amyloidogenic intermediates of transthyretin induce apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The most infectious prion protein particles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Systemic amyloidosis in England: an epidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

A long-term study of prognosis in monoclonal gammopathy of undetermined significance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Dangerous small B-cell clones.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Clinical aspects of systemic amyloid diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Secondary amyloidosis has decreased in patients with inflammatory joint disease in Finland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Decline in the incidence of renal failure due to amyloidosis associated with inflammatory rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Decreasing incidence of AA amyloidosis in Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Natural history and outcome in systemic AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Leukocyte chemotactic factor 2: A novel renal amyloid protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Leukocyte chemotactic factor 2 (LECT2)-associated renal amyloidosis: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Prevalence and morphology of leukocyte chemotactic factor 2-associated amyloid in renal biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Development of gastrointestinal beta2-microglobulin amyloidosis correlates with time on dialysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Liver biopsy discloses a new apolipoprotein A-I hereditary amyloidosis in several unrelated Italian families

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Renal apolipoprotein A-I amyloidosis: a rare and usually ignored cause of hereditary tubulointerstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Medullary amyloidosis associated with apolipoprotein A-IV deposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Hereditary systemic amyloidosis due to Asp76Asn variant β2-microglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Diagnosis and management of the cardiac amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

CMR for Assessment of Diastolic Function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

MR-relaxometry of myocardial tissue: significant elevation of T1 and T2 relaxation times in cardiac amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Cardiovascular magnetic resonance in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Cardiovascular magnetic resonance and prognosis in cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Ostertag revisited: the inherited systemic amyloidoses without neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Refinement in patient selection to reduce treatment-related mortality from autologous stem cell transplantation in amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Long term effect of renal transplantation on dialysis-related amyloid deposits and symptomatology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Effect of amyloidosis on long-term survival in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Long-term outcome of live donor kidney transplantation for renal amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Sudden death in nondilated cardiomyopathies: pathophysiology and prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Implantable cardioverter defibrillators in patients with cardiac amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Long term results of heart transplantation in patients with amyloid heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Cardiac transplantation using extended-donor criteria organs for systemic amyloidosis complicated by heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Antisense oligonucleotide suppression of serum amyloid A reduces amyloid deposition in mice with AA amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Eprodisate for the treatment of renal disease in AA amyloidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Interaction of the anthracycline 4'-iodo-4'-deoxydoxorubicin with amyloid fibrils: inhibition of amyloidogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

A prospective study of nutritional status in immunoglobulin light chain amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The liver in systemic amyloidosis: insights from 123I serum amyloid P component scintigraphy in 484 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloidosis: pathogenesis and new therapeutic options.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Collagen plays an active role in the aggregation of beta2-microglobulin under physiopathological conditions of dialysis-related amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Light and electron microscopy immunohistochemical characterization of amyloid deposits

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Electron Microscopic Observations on a Fibrous Component in Amyloid of Diverse Origins

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Outcome in Renal AL Amyloidosis After Chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Hereditary lysozyme amyloidosis - phenotypic heterogeneity and the role of solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Organ Transplantation in Hereditary Apolipoprotein AI Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Solid Organ Transplantation in AL Amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Hereditary transthyretin amyloidosis: molecular basis and therapeutical strategies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

X-ray diffraction studies on amyloid filaments

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

EDTA Registry centre survey, 1986. Report from the European Dialysis and Transplant Association Registry

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Measurement of apoptosis and proliferation of bone marrow plasma cells in patients with plasma cell proliferative disorders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Primary systemic amyloidosis with delayed progression to multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Serum amyloid-A protein concentration in inflammatory diseases and its relationship to the incidence of reactive systemic amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Amyloidosis in a nationwide series of 1666 subjects with rheumatoid arthritis who died during 1989 in Finland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The amyloidosis of juvenile rheumatoid arthritis--comparative studies in Polish and American children. I. Levels of serum SAA protein

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Prognosis in juvenile rheumatoid arthritis with systemic onset. A follow-up study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Beta 2-microglobulin associated amyloidosis: a vanishing complication of long-term hemodialysis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

End-stage renal disease in familial amyloidosis ATTR Val30Met

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

The classification of amyloid deposits in clinicopathological practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Quantitative assessment of myocardial T2 relaxation times in cardiac amyloidosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.171

Primary systemic amyloidosis: clinical and laboratory features in 474 cases.

31 March 2020

1 reference

12 December 2020

"A case of cardiac amyloidosis with syncope".

1 reference

12 December 2020

Renal biopsy findings in Belgium: a retrospective single center analysis

1 reference

12 December 2020

Amyloidosis in juvenile chronic polyarthritis

1 reference

12 December 2020

Dialysis support of patients with primary systemic amyloidosis. A study of 211 patients

1 reference

12 December 2020

Results, principles and pitfalls in the management of renal AA-amyloidosis; a 10-21 year followup of 16 patients with rheumatic disease treated with alkylating cytostatics

1 reference

12 December 2020

Chronic dialysis in patients with systemic amyloidosis: the experience in northern Italy

1 reference

12 December 2020

Renal transplantation in the amyloidosis of familial Mediterranean fever. Experience in ten cases

1 reference

12 December 2020

No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2013.171

1 reference

29 August 2017

1 reference

PubMed ID

23979488